The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II randomized study of first line avelumab with carboplatin-gemcitabine versus carboplatin-gemcitabine alone in patients with metastatic urothelial carcinoma ineligible for cisplatin-based therapy.
 
Alejo Rodriguez Vida
No Relationships to Disclose
 
Begona Mellado
No Relationships to Disclose
 
Xavier Garcia del Muro
Consulting or Advisory Role - Bristol-Myers Squibb; Ipsen; Lilly; Pfizer; PharmaMar; Roche
Speakers' Bureau - Pfizer
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Pfizer
 
Alvaro Taus
No Relationships to Disclose
 
Rafael Morales Barrera
No Relationships to Disclose
 
Pablo Maroto
No Relationships to Disclose
 
Teresa Bonfill
No Relationships to Disclose
 
Montserrat Domenech
No Relationships to Disclose
 
Alvaro Pinto
No Relationships to Disclose
 
Begona Perez Valderrama
No Relationships to Disclose
 
Miguel A. Climent
No Relationships to Disclose
 
Javier Puente
No Relationships to Disclose
 
Jose Luis Perez-Gracia
No Relationships to Disclose
 
Enrique González-Billalabeitia
No Relationships to Disclose
 
Federico Vazquez
No Relationships to Disclose
 
Susana Galtes
No Relationships to Disclose
 
Barbara Pons
No Relationships to Disclose
 
Sonia Macia
No Relationships to Disclose
 
Daniel E. Castellano
No Relationships to Disclose
 
Joaquim Bellmunt
Consulting or Advisory Role - Merck; Pfizer; Pierre Fabre